healthcare

This commercial med-tech is valued at just ~A$40m despite having innovative tech, market adoption and a partnership with a global giant.

Could this Australian-American healthcare stalwart hit $60/share?

Real Asset Management's Matthew Strotton is bullish on this often overlooked area of healthcare real estate investing.

In this wire, we explain why one of our flagship funds shifted to a full-time healthcare focus.

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a beneficiary.

Wilson Asset Management’s Dania Zinurova explains the big themes she chases for WAM Alternative Assets through her investments.

The Pharma & Biotech market had a relatively positive month with 41.5% of the coverage universe posting positive share price movements for the month of September. Over...

Why the healthcare sector could gain momentum even as economic growth potentially slows and the U.S. readies for a presidential election.

With volatility persisting investors may want to consider this defensive sector, supported by valuations and long-term growth drivers.

Numerous economic and geopolitical risks continue to remain on the horizon and are keeping many people up at night, not just investors.

It's been a wild ride for ResMed over the past couple of years and while there might be further volatility, things are back on track

Advances in healthcare are one of the greatest advantages of the times we live in and it's only getting more exciting (and profitable).

Murdoch sat down with James McDonald, PM at Pengana. We discuss key sectors, including healthcare, titanium, Japan, resources and more.

Plus, fund managers outline the key trends shaping the sector.

The healthcare sector is benefiting from rapid innovation, fuelled by a significant jump in COVID-led funding.

AI has enormous potential to improve healthcare delivery across the globe, and some practical applications could benefit investors.

With the healthcare sector in a deep and prolonged downturn, valuations of public and private R&D stage companies are very attractive.

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and the S&P/ASX Small Ordinaries Accumulation...

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.

Pulsed Field Ablation is the most exciting technology to come to market in many years, and offers great potential returns for the winners